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Background/Aims: Early diagnosis and appropriate antimicrobial choice are crucial when managing pneumonia 
patients, and quantitative culture of bronchoalveolar lavage (BAL) fluid is considered a useful method for identifying 
pneumonia pathogens. We evaluated the quantitative yield of BAL fluid bacterial cultures in patients being treated with 
antimicrobials and attempted to identify factors predictive of positive BAL cultures.
Methods: Patients over 18 years old and whose BAL fluid was subjected to quantitative culture to identify the organism 
causative of pneumonia between January 1, 2005, and December 31, 2009, were included. We reviewed the results of 
BAL fluid bacterial cultures and the clinical records, laboratory tests, and radiographic findings of the patients.
Results: BAL was performed on 340 patients with pneumonia. A positive BAL culture, defined as isolation of more 
than 104 colony forming units/mL bacteria, was documented in 18 (5.29%) patients. Of these, 9 bacteria isolated from 
10 patients were classified as probable pathogens. The most frequently isolated bacteria were methicillin-resistant 
Staphylococcus aureus, Acinetobacter baumannii, and Pseudomonas aeruginosa. No independent predictive factor for 
positive BAL cultures was identified. 
Conclusions: The yield of quantitative BAL fluid bacterial culture in patients already on antimicrobials was low. 
Clinicians should be cautious when performing a BAL culture in patients with pneumonia who are already on 
antimicrobials. 
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INTRODUCTION 
Pneumonia causes more deaths worldwide than any 
other infectious disease [1]. Although pneumonia can 
usually be cured with antimicrobials, patients can die if 
prompt, appropriate, and adequate therapy is not initi-
ated [2]. Early diagnosis and proper choice of antimi-
crobials are crucial for successful management of pneu-
monia [3]. Bronchoalveolar lavage (BAL) and protected 
specimen brush are standard methods for identifying 
causative organisms [4,5]. The usefulness of endoscopic 
procedures, especially BAL, is well-established in both Kim Es, et al. Yield from quantitative culture of bronchoalveolar lavage fluid    157
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immunocompetent and immunocompromised patients 
with pneumonia [6-8]. BAL aids in identifying causative 
organisms in 50-70% of cases, which varies with both 
the type of pneumonia and the patient population [9-11]. 
However, previous antimicrobial therapy decreases the 
yield and accuracy of BAL for isolation of pneumonia-
causing organisms. Unfortunately, BAL is usually per-
formed in referral hospitals, where clinicians encounter 
patients with pneumonia who are already being treated 
with antimicrobials. The aim of this study was to deter-
mine the yield of quantitative BAL fluid bacterial cul-
ture in patients being treated with antimicrobial agents. 
We also attempted to identify factors predictive of posi-
tive BAL cultures.
METHODS
Study design and participants
Patients over 18 years of age in whom BAL through 
flexible bronchoscopy was performed to identify pneu-
monia-causing organisms from January 1, 2005, to 
December 31, 2009, at Seoul National University Hos-
pital, a tertiary-referral university-affiliated hospital in 
Korea, were included in this retrospective cohort study. 
The protocol was approved by the ethics review com-
mittee of the hospital.
Review of clinical records
Patient demographics (gender, age, and smoking sta-
tus) and clinical characteristics (comorbidities, symp-
toms, and physical signs) were obtained and reviewed. 
Results of laboratory tests and radiographic studies 
were also reviewed. 
BAL procedure
Flexible bronchoscopy was performed using a stan-
dard protocol. Bronchoscopic examinations were per-
formed by full-time faculty staff or fellows in the pul-
monology division, and one or two well-trained nurses 
assisted the bronchoscopist with each procedure. A 5.9 
mm diameter bronchoscope (model BF-1T240 or BF-
1T260; Olympus Optical Co., Tokyo, Japan) was used. 
After advancing the bronchoscope through the vocal 
cords, 5 mL 1% lidocaine solution was infused through 
the scope, and additional volumes of 1% lidocaine solu-
tion were infused if needed during the procedure, with 
a maximum allowed dose of 5 mg/kg. After wedging the 
bronchoscope into subsegmental bronchi of the involved 
lesion, BAL was conducted using three or four 50 mL 
aliquots of sterile 0.9% warm saline infused through 
the working channel of the bronchoscope. Retrieved 
fluid was sent immediately to the Department of Clini-
cal Microbiology for quantitative bacterial culture. BAL 
fluid was stained and cultured for aerobic and anaerobic 
bacteria, fungi (Aspergillus and Candida species), my-
cobacteria, and viruses. Bacteria present at a concen-
tration of 1 × 10
3 colony forming units (CFU)/mL BAL 
specimen or higher were identified.
Definitions
Pneumonia
Pneumonia was defined as a new, progressive, or 
persistent (> 24 hours) infiltrate on a chest radiograph 
when two or more of the following criteria were met: 
macroscopic purulent sputum; temperature of > 38.5°C 
or < 36.5°C; leukocytosis of 10,000 cells/µL or more, or 
leukopenia of less than 4,000 cells/µL; and dyspnea or 
worsening of respiratory status. 
Positive quantitative bacterial culture from BAL fluid
A positive quantitative culture was defined when bac-
teria were cultured from BAL samples at a concentra-
tion of 1 × 10
4 CFU/mL or more.
Classification of isolates
True pathogens were defined as aerobic Gram-positive 
bacteria (Streptococcus pneumoniae, Staphylococcus 
aureus, and Group A hemolytic streptococci), aerobic 
Gram-negative bacteria (Klebsiella pneumoniae and 
Hemophilus influenzae), and atypical pathogens (Chla-
mydia pneumoniae or Mycoplasma pneumoniae), or an 
organism that could account for the clinical features of 
the patient. Probable colonizers or contaminants were 
defined as isolates obtained from BAL cultures that did 
not meet the criteria for a true pathogen.
Multidrug-resistant bacteria
Multidrug-resistant (MDR) bacteria included methicil-
lin-resistant S. aureus, methicillin-resistant coagulase-
negative staphylococci, vancomycin-resistant entero-158    The Korean Journal of Internal medicine Vol. 27, No. 2, June 2012
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cocci, S. pneumoniae resistant to penicillin and other 
broad-spectrum agents such as macrolides and fluoro-
quinolones, and MDR Gram-negative bacilli [12]. MDR 
Gram-negative bacilli included Klebsiella spp., Entero-
bacter cloacae, and Escherichia coli resistant to at least 
three of the following antimicrobial groups: third- or 
fourth-generation cephalosporins, aminoglycosides, 
fluoroquinolones, piperacillin, or ampicillin/sulbactam. 
Pseudomonas aeruginosa that was resistant to at least 
three of the following antimicrobial groups was also 
classified as an MDR Gram-negative bacillus: ceftazi-
dime, cefepime, aminoglycosides, fluoroquinolones, 
carbapenems, and piperacillin. Acinetobacter bauman-
nii, which is resistant to all antimicrobial agents, or all 
except imipenem, and organisms such as Stenotroph-
omonas maltophilia, which are intrinsically resistant to 
the broadest spectrum antimicrobial agents, were also 
considered MDR bacteria [12,13].
Treatment modification
Treatment modifications were defined as any change 
in antibiotic treatment, such as switching to another an-
tibiotic, prolongation of antibiotic treatment, or supple-
mentation of the preexisting antibiotic regimen.
Statistical analysis 
Analyses were performed using Pearson’s chi square 
test or Fisher’s exact test for categorical variables, and 
Student’s t test for continuous variables. The follow-
ing variables were tested as possible predictors: extent 
of pneumonia (1/2 of lung), intensive care unit stay, 
duration of antimicrobial use before performing BAL, 
previous solid organ transplantation, and current use of 
corticosteroids. Variables with a p < 0.20 in univariate 
comparisons were subjected to multiple logistic regres-
sion to identify predictors of positive BAL cultures. 
Backward elimination was used in the logistic regres-
sion to select variables for the final model, and p < 0.05 
was used as the criterion for significance of the associa-
tions. All statistical analyses were performed with SPSS 
version 17.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline characteristics of patients
BAL was performed on 340 patients with pneumonia, 
comprising 248 men and 92 women with a median age 
of 64 years (range, 19 to 90). All patients were already 
on antimicrobials for treatment of pneumonia when 
BAL was performed. The median duration of antimicro-
bial use before performing BAL was 6 days (range, 1 to 
114). Other demographic and clinical characteristics of 
the patients are shown in Table 1. 
BAL quantitative culture
A positive BAL culture (> 10,000 colonies) was docu-
mented in 18 (5.29%) patients, and 25 microorganisms 
were isolated at concentrations above the diagnostic 
threshold. Among them, 9 probable pathogens were iso-
Table 1. Baseline characteristics of 340 patients with 
pneumonia in whom bronchoscopic  bronchoalveolar 
lavages (BALs) were performed  
Variables  Total (n = 340)
male  248 (72.9)
Age, yr    64 (19-90)
Never smoker  129 (37.9)
History of previous tuberculosis    43 (12.6)
solid organ transplantation    44 (12.9)
Current use of corticosteroid  164 (48.2)
Comorbidity   
Diabetes    53 (15.6)
Chronic kidney disease
a
    36 (10.6)
Chronic obstructive pulmonary disease   16 (4.7)
Interstitial lung disease    12 (3.5)  
malignancy  205 (60.3)
symptoms/signs 
Fever (≥ 38.3°C)  223 (65.6)
sputum  290 (85.3)
Dyspnea  295 (86.8)
Extent of pneumonia (> 1/2 of one lung)  280 (82.8)
stay in ICU when performing BAL    36 (10.6)
Duration of antimicrobials use before     
 performing BAL, day 
    6 (1-114)
Values are presented as number (%) or median (range).
ICU, intensive care unit.
aChronic kidney disease is defined as a decreased kidney 
glomerular filtration rate < 60 mL/min/1.73 m
2 for ≥ 3 mon. Kim Es, et al. Yield from quantitative culture of bronchoalveolar lavage fluid    159
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lated from 10 patients (2.94%). A polymicrobial infec-
tion was present in three patients. The most frequently 
isolated species were methicillin-resistant S. aureus 
(four patients), A. baumannii (four patients), and P. ae-
ruginosa (three patients) (Table 2).
Factors predictive of BAL culture-positivity
Patients with or without a cultured pathogen did not 
differ significantly with regard to comorbidities, clini-
cal signs and symptoms, pneumonia extent, or duration 
of antimicrobial use before BAL (Table 3). Based on the 
clinical variables included in the univariate comparison 
of patients in the culture-positive and culture-negative 
groups, the final multiple logistic regression model pre-
dicting positive BAL cultures included age, presence of 
dyspnea, duration of antimicrobial use before BAL, and 
the extent of pneumonia. However, no independent pre-
dictive factor for positive BAL cultures was identified 
(Table 4).
Impact of BAL results on treatment
Treatment was modified in 6 of 10 patients with a 
probable pathogen identified in BAL fluid. Clinical im-
provement, such as a decreased need for a ventilator 
and a decreased extent of pulmonary infiltrates, was 
documented in four of six patients (67%). 
DISCUSSION
Culture of BAL fluid was used to identify pneumonia-
causing organisms. We found that the quantitative 
BAL fluid bacterial culture yield was as low as 2.94% in 
patients with pneumonia who were already on antimi-
crobials. This yield is much lower than that of previous 
studies, which reported 30-80% culture rates [14-17], 
possibly due to use of antimicrobials before BAL. Pre-
culture antimicrobials significantly decrease the yield 
of blood and sputum cultures [18-21]. Furthermore, the 
long duration of antimicrobial treatment in our study 
(45% of patients received antimicrobials for more than 1 
Table 2. Cultured organisms more than 10,000 colonies from quantitative culture of BAL fluid 
Organisms  Total (n = 25) No. of mDR strains
Probable pathogen  16 (64) 12 (75)
Gram-positive bacteria  7 (28) 4 (57)
Staphylococcus aureus methicillin resistant  4 (16) 4 (100)
Streptococcus pneumonia  2 (8) 0 (0)
staphylococcus aureus methicillin sensitive  1 (4) 0 (0)
Gram-negative bacteria  9 (36) 8 (89)
Acinetobacter baumanii  4 (16) 4 (100)
Pseudomonas aeruginosa  3 (12) 2 (67)
Sternotrophomonas maltophilia  1 (4) 1 (100)
Enterobacter aerogenes  1 (4) 1 (100)
Probable colonizer/contaminants  9 (36) 5 (56)
Gram-positive bacteria  5 (20) 4 (60)
Staphycococcus edpidermidis methicillin resistant  2 (8) 2 (100) 
Staphylococcus hemolyticus methicillin resistant  1 (4) 1 (0)
Enterococcus faecium  1 (4) 1 (100)
Corynebacterium species  1 (4) 0 (0)
Gram-negative bacteria  2 (8) 1 (50)
Escherichia coli  1 (4) 0 (0)
Bukholderia cepacia  1 (4) 1 (100)
Yeast  2 (8) 0 (0)
Values are presented as number (%).
BAL, bronchoalveolar lavage; mDR, multidrug-resistant. 160    The Korean Journal of Internal medicine Vol. 27, No. 2, June 2012
               
http://dx.doi.org/10.3904/kjim.2012.27.2.156 http://www.kjim.or.kr
week before BAL) may have further decreased the yield. 
In a prior study, if BAL was performed within 3 days of 
starting antimicrobials, the overall yield was 63.4%, but 
decreased to 57.6% and 34.4% when performed within 
3-14 days and after 14 days, respectively [14]. In ad-
dition, frequent use of wide-spectrum antimicrobials 
could decrease the yield of BAL fluid culture [22].
Despite the low BAL fluid culture yield, treatment 
was modified in 6 of 10 patients with a probable patho-
gen identified by BAL fluid culture; of these, 4 patients 
improved clinically. The other two patients from whom 
MDR pathogens (methicillin-resistant S. aureus and A. 
baumannii) were isolated deteriorated and died after a 
few days, even though pathogen-specific antimicrobi-
als were administered immediately. Given that clinical 
improvement was achieved in four of six patients with a 
cultured pathogen, BAL culture is useful for determina-
tion of the appropriate antimicrobial therapy after isola-
tion of a pathogen. 
The majority of organisms cultured from BAL fluid 
were MDR bacteria (12 cases, 75%). The frequent isola-
tion of MDR bacteria from our study population might 
be associated with the fact that our patient cohort had 
well-known risk factors for MDR bacteria, such as a 
Table 3. Comparisons of characteristics between patients with/without identified pathogens from BAL fluid 
Characteristics 
Culture positive group 
(n = 18)
Culture negative group 
(n = 322)
p value
sex (male)     11 (61.1) 237 (73.6) 0.246
Age, yr  55.5 (27-75) 64.0 (19-90) 0.038
History of previous tuberculosis  0 (0) 43 (13.4) 0.097
solid organ transplantation  1 (5.6) 11 (3.4) 0.632
Current use of corticosteroid  8 (44.4) 156 (48.4) 0.741
Comorbidities 
Diabetes  3 (16.7) 50 (15.5) 0.897
Chronic kidney diseases
a
  0 (0) 36 (11.2) 0.134
COPD  0 (0) 16 (5.0) 0.333
Interstitial lung diseases  1 (5.6) 11 (3.4) 0.632
malignancy  12 (66.7) 193 (59.9) 0.570
symptoms/signs 
Fever (≥ 38.3°C)  10 (55.6) 213 (66.1) 1.135
sputum  17 (94.4) 273 (84.8) 0.260
Dyspnea  13 (72.2) 282 (87.9) 0.055
Extent of pneumonia (> 1/2 of one lung)  12 (66.7) 268 (83.8) 0.061
stay in ICU when performing BAL  10 (55.6) 26 (8.07) 0.390
Duration of antimicrobials use before performing BAL, day  8.5 (1-37)   6 (1-114) 0.299
Values are presented as number (%) or median (range).
BAL, bronchoalveolar lavage; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit. 
aChronic kidney disease is defined as a decreased kidney glomerular filtration rate < 60 mL/min/1.73 m
2 for ≥ 3 mon.
Table 4. Predictors of pathogen isolation through bronchoalveolar lavage (BAL) quantitative culture
a 
Variables Hazard ratio 95% confidence interval p value
Age  0.974 0.945-1.004 0.094
Presence of dyspnea  2.424 0.736-7.988 0.145
Duration of antimicrobials use before performing BAL, day  1.014 0.985-1.045 0.339
Extent of pneumonia (> 1/2 of one lung)  1.748 0.558-5.479 0.338
aHosmer-Lemeshow goodness of fit: p value 0.812. Kim Es, et al. Yield from quantitative culture of bronchoalveolar lavage fluid    161
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nosocomial infection, admission within the previous 3 
months, mechanical ventilation, indwelling central ve-
nous catheterization, and bladder catheterization [23]. 
Many previous studies focused on BAL quantitative 
cultures in patients with ventilator-associated pneumo-
nia (VAP). However, we included not only VAP, but also 
community-acquired pneumonia and nursing-care-
associated pneumonia to evaluate the overall yield of 
bacteria from BAL fluid cultures. Because the overall 
yield from quantitative BAL fluid cultures in patients on 
antimicrobials was very low, BAL performance before 
initiating antimicrobial treatment may be more appro-
priate, or its use should be delayed until prior antimi-
crobial therapy has proven ineffective.
The limitations of this study must be acknowledged. 
First, it was a retrospective design. Because the decision 
to perform BAL fluid quantitative culture depended on 
the individual clinician, confounding factors affecting 
the results could not be controlled for. In addition, we 
found no factors predictive of BAL culture-positivity. 
Positive cultures were not associated with the extent of 
pneumonia or duration of antimicrobial use before the 
procedure; this may have been due to the very low BAL 
yield.
In conclusion, the quantitative BAL fluid bacterial 
culture yield for identification of pathogens causing 
pneumonia in patients already on antimicrobials was 
very low. Clinicians should exercise caution when decid-
ing whether to perform a BAL culture in patients with 
pneumonia who are already on antimicrobials.
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